GSK China Appoints Sherman Yu as New General Manager Amid Leadership Transition

May 10, 2024 16:01 CST Updated 16:01

GSK

Pharmaceutical R&D Manufacturer

Yesterday evening, Mike Crichton, Senior Vice President of GSK Greater China and Intercontinental Region (GSK GCI), announced a major personnel change to the employees.Cecilia Qi, currently Vice President of GSK and General Manager of China, has been appointed as Vice President of GSK for Greater China and Intercontinental Regions and Head of Vaccines Business, with Sherman Yu taking over her role as Vice President of GSK and General Manager of China.。

Yu Huiming is currently the Vice President of GSK and General Manager of Taiwan, China. According to Dami's information, the two will officially hand over on June 1st and assume their new positions on July 1st respectively.

Qi Xin assumed the position of General Manager of GSK China in January 2020, succeeding Fabio Landazabal, who was then Senior Vice President of GSK, General Manager of Emerging Markets and China, and was transferred to the position of General Manager of Italy. Qi Xin, who was then Vice President of GSK, General Manager of China Vaccines and Greater Bay Area, took over as General Manager of GSK China (see MRCLUB historical news:GSK Welcomes Its First Chinese General Manager! She is a 16-Year Veteran Employee Who Once Oversaw the Vaccine Business）。

Over the past four years, under the leadership of Qi Xin, GSK's business in China has undergone significant changes. According to official reports, 21 new products and indications have been successfully approved and launched in China, including blockbuster products such as Shingrix, Nucala, and Benlysta.

For many pharmaceutical professionals, Yu Huiming, who has taken over as General Manager of GSK China, is no stranger. She previously worked at Novartis Sandoz and served as President of Greater China.。

Yu Huiming has over two decades of experience in the Chinese pharmaceutical market, previously introduced by Dami. Before joining Sandoz, Yu Huiming held roles in business management and marketing at Wyeth and Pfizer Vaccines. In August 2012, she joined Sandoz as the General Manager for the Hong Kong region, later overseeing Sandoz's operations in Hong Kong and Taiwan. In March 2019, Sandoz officially announced the establishment of the "Greater China Region," with Francis Vaillant, the current head of Southeast Asia and North Asia, appointed as the President of the Greater China Region. In May of the same year, Yu Huiming was appointed as the Chief Operating Officer of Sandoz Greater China. In early 2022, Yu Huiming officially assumed the role of President of Sandoz Greater China.

On August 24, 2022, it was announced that Yu Huiming would leave Sandoz on September 28, stating, "I hope to further challenge myself through external learning. Leaving Sandoz is a very difficult personal decision." (See MRCLUB historical message:President of Sandoz Greater China Region Departs from Position）。

The day after Yu Huiming announced her resignation, Novartis announced that it would spin off Sandoz as a new independent publicly traded company (see MRCLUB historical news:Novartis announces the spin-off of Sandoz）。

On October 4, 2023, Sandoz was listed as an independent company on the Swiss Stock Exchange. Two months later, based on the swap agreement for the European sales license rights of Sandoz China and Aspen Surgical Anesthesia portfolios, Sandoz's operations in China were integrated into Aspen (see MRCLUB historical messages).Breaking! Sandoz China Sold in Entirety, Employees to Be Integrated Into This Company）。

After leaving Sandoz, Yu Huiming joined GSK, taking up the position of Vice President and General Manager for the Taiwan region.

This time, GSK’s return to the Chinese market shows that it highly values Ming Huiyu's experience and leadership in the Chinese market, expecting him to play a significant role in promoting GSK's business development in China.